J&J submits PMA for personalized sedation
This article was originally published in The Gray Sheet
Executive SummaryEthicon Endo-Surgery unit of Johnson & Johnson submits PMA application to FDA for its Sedasys computer-assisted personalized sedation system. The device is intended for use by physician/nurse teams to administer minimal to moderate doses of propofol to sedate patients undergoing colonoscopies for the diagnosis and screening of colorectal cancer, as well as upper gastrointestinal disorders. The PMA is supported by a 1,000-patient, U.S. trial randomizing Sedasys to the current standard of care, which consists of physician-administered benzodiazepine and opioids
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.